Why is significant variability within brain death protocol permitted from hospital to hospital? Have there been any medical legal precedents attributed to the inconsistency of these guidelines? What would be the most appropriate approach to addressing these concerns? Dr. Greer shares his thoughts, in the context of his research, with host Dr. Mark Nolan Hill.
advertisement
The Future of Brain Death Protocol
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Dr. David Greer, assistant professor of neurology at Harvard Medical School, directed a national survey of the leading neurology and neurosurgery programs to analyze policies for making brain death declarations. Though American medical institutions are not required to follow parameters for determining brain death, as published by the American Academy of Neurology, Dr. Greer’s report shows significant variation in the guidelines at surveyed institutions.
Recommended
Details
Presenters
Overview
Dr. David Greer, assistant professor of neurology at Harvard Medical School, directed a national survey of the leading neurology and neurosurgery programs to analyze policies for making brain death declarations. Though American medical institutions are not required to follow parameters for determining brain death, as published by the American Academy of Neurology, Dr. Greer’s report shows significant variation in the guidelines at surveyed institutions. Why is significant variability within brain death protocol permitted from hospital to hospital? Have there been any medical legal precedents attributed to the inconsistency of these guidelines? What would be the most appropriate approach to addressing these concerns? Dr. Greer shares his thoughts, in the context of his research, with host Dr. Mark Nolan Hill.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
<p>New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure</p>
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 credits
<p>Partnering with Patients: Building Effective Communication and Support in HF Care</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
1.25 credits
<p>Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?